This Biotech’s Mission Is To Go Global – And Revolutionize Cancer Treatment
“We have a $5 billion market cap now. The next stage is for us to get to $20 billion,” declares the chief executive of the…
Biotech
This Immuno-Oncology Stock Could Be A Compelling Short-Term Play (Or Long-Term Investment)
The clinical-stage biotech highlighted in today’s article – operating in the hot immuno-oncology sector – has both long-term and short-term bull cases to be made…
A Promising Biotech IPO – And Its Potential Problems
Gossamer Bio is a San Diego-based biotech that is readying for an initial public offering – and with a diverse pipeline including potential treatments for…
Are These Stocks The “Hidden Gems” Of This Earnings Season?
The five stocks highlighted in today’s article were not big headline-grabbers this earnings season, yet they each had surprisingly positive numbers to report despite recent…
These 3 Biotech Stocks May Be The Best Pure Plays On Two Remarkable Advances In Cancer Treatment
A number of conferences have recently taken place where cancer researchers have revealed the latest and most promising developments in the fight against this disease.…
The 21st Century Cures Act: How Investors Can Profit From This Potential “Boon For Big Pharma”
Today’s article notes that it takes almost $1 billion to bring a new drug to market, stifling competition and allowing drug companies to charge Americans…
4 Biotechs To Consider On The Sector’s Trump Turnaround
After being weighted down this year by the prospect of a Hillary Clinton administration focused on curbing drug prices, biotechs have seen a recovery since…
- « Previous
- 1
- 2